AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20050300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture applied to acupuncture points PC6 and HT7 for 20 minutes twice a week for 8 weeks
Number of subjects: 33
Study 20050300 — intervention group
Group type: COMPARATOR
Intervention: Control group continued rehabilitation without electroacupuncture
Number of subjects: 33
Study 20050300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 33
Study 20050300 — intervention group
Group type: COMPARATOR
Intervention: Control group continued rehabilitation
Number of subjects: 33
Study 16996224 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (ContM) - only
Number of subjects: 240
Study 16996224 — intervention group
Group type: EXPERIMENTAL
Intervention: MET+CBT+ContM
Number of subjects: 240
Study 16996224 — intervention group
Group type: COMPARATOR
Intervention: MET+CBT
Number of subjects: 240
Study 16996224 — intervention group
Group type: COMPARATOR
Intervention: Case-management control condition
Number of subjects: 240
Study 14742374 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 3
Study 14742374 — intervention group
Group type: EXPERIMENTAL
Intervention: One type of HME
Number of subjects: 3
Study 14742374 — intervention group
Group type: EXPERIMENTAL
Intervention: Other HMEs
Number of subjects: 3
Study 11286433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pergolide
Number of subjects: 255
Study 11286433 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose pergolide
Number of subjects: 255
Study 11286433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 9451466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month individualized progressive resistance training programme (moderate intensity, high volume) twice a week
Number of subjects: 38
Study 7938786 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic presentation procedure
Number of subjects: 16
Study 7938786 — intervention group
Group type: COMPARATOR
Intervention: Static presentation procedure
Number of subjects: 16
Study 2896359 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (4 mg daily, increased if necessary over 4 weeks)
Number of subjects: 53
Study 2896359 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperon (75 mg daily, increased if necessary over 4 weeks)
Number of subjects: 53
Study 2896359 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Zuclopenthixol and Melperon)
Number of subjects: 53
Study 30928088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with real time registry, navigator, and clinical feedback.
Number of subjects: 302
Study 30928088 — intervention group
Group type: COMPARATOR
Intervention: Retrospective control group (Blacks 79.8% vs. Whites 87.3%, p < 0.001).
Number of subjects: 302
Study 30928088 — intervention group
Group type: COMPARATOR
Intervention: Concurrent control group (Blacks 83.1% vs. Whites 90.1%, p < 0.001).
Number of subjects: 302
Study 30928088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group compared to retrospective control for Blacks.
Number of subjects: 302
Study 30928088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group compared to concurrent control for Blacks.
Number of subjects: 302
Study 31277595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-HMB (exercise intervention with HMB)
Number of subjects: 104
Study 31277595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-Plac (exercise intervention with placebo)
Number of subjects: 104
Study 31277595 — intervention group
Group type: EXPERIMENTAL
Intervention: NoEx-HMB (no exercise intervention with HMB)
Number of subjects: 104
Study 31277595 — intervention group
Group type: COMPARATOR
Intervention: Controls (No exercise and no HMB)
Number of subjects: 104
Study 29137500 — intervention group
Group type: COMPARATOR
Intervention: Philani+ intervention using community health workers (Mentor Mothers) for pre- and postnatal home visits over twenty-four months.
Number of subjects: 0
Study 29137500 — intervention group
Group type: COMPARATOR
Intervention: Philani+ intervention
Number of subjects: 0
Study 26738450 — intervention group
Group type: EXPERIMENTAL
Intervention: DLX105 (single-chain anti-TNF-α antibody)
Number of subjects: 0
Study 26738450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26738450 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DLX105 (0.5% hydrogel formulation)
Number of subjects: 0
Study 26738450 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DLX105 with weekly tape stripping
Number of subjects: 0
Study 25074252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin reload (325 mg orally)
Number of subjects: 91
Study 25074252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reload)
Number of subjects: 91
Study 22815989 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg, simvastatin 40 mg)
Number of subjects: 86
Study 22815989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19717646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (300 mg/day for 5 days)
Number of subjects: 66
Study 19717646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 17300594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice daily (b.i.d.)
Number of subjects: 28
Study 17300594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15144392 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ALA preparation in Eucerin cream applied under an occlusive dressing followed by irradiation with 75 J/cm² of broad-band red light.
Number of subjects: 9
Study 15144392 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with only light or only ALA.
Number of subjects: 9
Study 11176160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 26
Study 11176160 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rotational therapy
Number of subjects: 26
Study 11176160 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide (NO) therapy
Number of subjects: 26
Study 9498634 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically targeted prediction strategy
Number of subjects: 0
Study 9498634 — intervention group
Group type: COMPARATOR
Intervention: Pure immunological strategy
Number of subjects: 0
Study 8567093 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 200 mg/week
Number of subjects: 36
Study 8567093 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements before injections)
Number of subjects: 36
Study 2293809 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple component smoking cessation program
Number of subjects: 0
Study 2293809 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 13088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-wave biofeedback training (10 hour-long sessions over 3 weeks)
Number of subjects: 25
Study 13088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-wave biofeedback training
Number of subjects: 25
Study 13088 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched)
Number of subjects: 25
Study 30230970 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session positive cognitive intervention
Number of subjects: 79
Study 28781130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial application of 0.5‐5×10^6 CD133+
Number of subjects: 82
Study 28781130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5ml)
Number of subjects: 82
Study 28781130 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (R) classified by ∆LVEF≥5% after 180d
Number of subjects: 82
Study 28781130 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (NR)
Number of subjects: 82
Study 28781130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean survival time for responders (R)
Number of subjects: 82
Study 25298176 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of interleukin-6 at baseline
Number of subjects: 3794
Study 25298176 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in blood pressure
Number of subjects: 3794
Study 25298176 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of endothelial function, renal function, and glucose homeostasis
Number of subjects: 3794
Study 23157368 — intervention group
Group type: EXPERIMENTAL
Intervention: ResMed continuous-positive-airway-pressure mask (CM)
Number of subjects: 30
Study 23157368 — intervention group
Group type: COMPARATOR
Intervention: Standard mask (SM)
Number of subjects: 30
Study 22072367 — intervention group
Group type: EXPERIMENTAL
Intervention: BREAD meal (2.39 MJ, with equal caloric distribution including bread)
Number of subjects: 122
Study 22072367 — intervention group
Group type: COMPARATOR
Intervention: NO BREAD meal (2.40 MJ, with equal caloric distribution excluding bread)
Number of subjects: 122
Study 19300425 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 x 7 g/day)
Number of subjects: 12
Study 17542207 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations (Z‐250)
Number of subjects: 50
Study 17542207 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite restorations (Z‐250 and RelyX)
Number of subjects: 50
Study 17542207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inlays (Vitadur Alpha)
Number of subjects: 50
Study 17542207 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional amalgam restorations (GS‐80)
Number of subjects: 50
Study 17542207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations
Number of subjects: 50
Study 17542207 — intervention group
Group type: COMPARATOR
Intervention: Control group (human caries-free premolars)
Number of subjects: 50
Study 14767023 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection therapy (PEIT)
Number of subjects: 19
Study 14767023 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol injection therapy (PCIT)
Number of subjects: 19
Study 11434842 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐to‐Family Network intervention (15-month duration)
Number of subjects: 193
Study 11434842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 193
Study 11434842 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐to‐Family Network intervention
Number of subjects: 193
Study 9733503 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P antagonist MK-869
Number of subjects: 0
Study 9733503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7912347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg cladribine
Number of subjects: 51
Study 7912347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 51
Study 7912347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 51
Study 7912347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1933601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 3 years or 4 years
Number of subjects: 14
Study 1933601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 3 years
Number of subjects: 14
Study 1933601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 2 years
Number of subjects: 14
Study 1933601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily
Number of subjects: 14
Study 1933601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 319936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine, 120 mg/day for 10 or more days
Number of subjects: 0
Study 31609714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral motor priming
Number of subjects: 16
Study 31609714 — intervention group
Group type: COMPARATOR
Intervention: Health care education followed by task specific training
Number of subjects: 16
Study 31585425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA)
Number of subjects: 209
Study 31585425 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluorescein (fluorescein)
Number of subjects: 209
Study 28426239 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pancreas (AP) system using the DiAs Control Platform software
Number of subjects: 12
Study 28426239 — intervention group
Group type: COMPARATOR
Intervention: Usual insulin pump + continuous glucose monitor (CGM) care at home
Number of subjects: 12
Study 25354554 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 306
Study 25354554 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 306
Study 25354554 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between chemotherapy and genotype
Number of subjects: 306
Study 23821768 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone or olanzapine dose reduction (50% in 4 weeks, maintained thereafter)
Number of subjects: 61
Study 23821768 — intervention group
Group type: COMPARATOR
Intervention: Maintenance group (dose kept constant)
Number of subjects: 61
Study 16197959 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched training (interactive web tutorial and live remote observation)
Number of subjects: 12
Study 16197959 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (overview of scoring conventions, watching and scoring videotapes, observation of interviews)
Number of subjects: 12
Study 12827399 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 12827399 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study 12827399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10328247 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 8682758 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated, manual-based, psychoeducational preventive intervention
Number of subjects: 54
Study 8682758 — intervention group
Group type: COMPARATOR
Intervention: Standardized lecture-group discussion
Number of subjects: 54
Study 1514532 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride administration
Number of subjects: 5
Study 6151503 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive regimens containing a beta-blocker (oxprenolol)
Number of subjects: 6357
Study 6151503 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive therapy not containing a beta-blocker
Number of subjects: 6357
Study 31706300 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 319
Study 31706300 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 319
Study 31706300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 27569432 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious digital rectal examination
Number of subjects: 35350
Study 27569432 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal prostate specific antigen (4 ng/ml or greater)
Number of subjects: 35350
Study 27569432 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious digital rectal examination and abnormal prostate specific antigen (combined)
Number of subjects: 35350
Study 27569432 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 35350
Study 27569432 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant prostate cancers detected
Number of subjects: 35350
Study 27569432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer specific deaths
Number of subjects: 35350
Study 25356632 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg/day)
Number of subjects: 114
Study 25356632 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4-6 mg/day)
Number of subjects: 114
Study 25356632 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 114
Study 23786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yoghurt with 1.9 g/d plant stanols as esters
Number of subjects: 70
Study 23786762 — intervention group
Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 70
Study 21669582 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 60
Study 21669582 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 60
Study 19941671 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound
Number of subjects: 800
Study 19941671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 800
Study 19941671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 800
Study 16523249 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in foster care
Number of subjects: 182
Study 12972102 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-1 treatment
Number of subjects: 60
Study 12972102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10732848 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitor (simvastatin)
Number of subjects: 15
Study 10732848 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 15
Study 9206241 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhinu (ZN) ‐I, ‐II
Number of subjects: 61
Study 9206241 — intervention group
Group type: COMPARATOR
Intervention: prednisone
Number of subjects: 61
Study 1358218 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate opening of colostomy
Number of subjects: 100
Study 1358218 — intervention group
Group type: COMPARATOR
Intervention: Delayed opening of colostomy
Number of subjects: 100
Study 1358218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 6199602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (3 X 40 mg daily for 6 weeks)
Number of subjects: 14
Study 6199602 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (single oral dose of 40 mg)
Number of subjects: 14
Study 29898009 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile fibromyalgia (JFM)
Number of subjects: 150
Study 29898009 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyarticular juvenile idiopathic arthritis (JIA)
Number of subjects: 150
Study 29898009 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study 30238438 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct endoscopy
Number of subjects: 66
Study 30238438 — intervention group
Group type: COMPARATOR
Intervention: No duct endoscopy
Number of subjects: 66
Study 26749408 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg intravenously
Number of subjects: 20
Study 26749408 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg orally
Number of subjects: 20
Study 26749408 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 600 mg once daily
Number of subjects: 20
Study 24989620 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT intervention (1-year programme including audit, feedback, goal setting, leadership programme, staff training, testing systems, exchange with researchers)
Number of subjects: 6
Study 24989620 — intervention group
Group type: COMPARATOR
Intervention: Control group (agencies not receiving the intervention during the initial phase)
Number of subjects: 6
Study 22201295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg (15-minute infusion)
Number of subjects: 24
Study 22201295 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin 2 g (5-minute infusion)
Number of subjects: 24
Study 20063994 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol 3‐hourly (group A)
Number of subjects: 118
Study 20063994 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol 6‐hourly (group B)
Number of subjects: 118
Study 20063994 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol 12‐hourly (group C)
Number of subjects: 118
Study 17727927 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical surgery
Number of subjects: 0
Study 17727927 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drug regimens for neoadjuvant chemotherapy
Number of subjects: 0
Study 16084162 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior (AP) electrode position
Number of subjects: 123
Study 16084162 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral (AL) electrode position
Number of subjects: 123
Study 12693427 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (50-300 mg daily)
Number of subjects: 0
Study 12693427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10408059 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine Position (SP)
Number of subjects: 56
Study 10408059 — intervention group
Group type: COMPARATOR
Intervention: Lateral Position (LP)
Number of subjects: 56
Study 7591492 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard weekly intervention (6 weekly sessions)
Number of subjects: 156
Study 7591492 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend intensive (2-day program)
Number of subjects: 156
Study 1981077 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 47
Study 1981077 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 47
Study 6794980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordette (30 microgram ethinyl estradiol and 150 microgram d-norgestrel)
Number of subjects: 36
Study 6794980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiol (50 microgram ethinyl estradiol and 250 microgram d-norgestrel)
Number of subjects: 36
Study 6794980 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasil (50 microgram ethinyl estradiol and 50 microgram d-norgestrel X 11 days and 125 microgram d-norgestrel X 10 days)
Number of subjects: 36
Study 6794980 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 36